brand logo

Am Fam Physician. 2023;107(6):568

Author disclosure: No relevant financial relationships.

To the Editor: As a psychiatrist and family physician, I appreciated the excellent coverage of schizophrenia by Drs. Crawford and Go.1 I agree that refractory schizophrenia should be treated with clozapine (Clozaril), often earlier during care than is commonly administered. However, clozapine is not available in the United States in a long-acting injectable form, although this would be a wonderful addition to our armamentarium. There are protocols in the U.K.'s Public Health Service for the use of intramuscular clozapine in treatment-refractory psychosis using an unlicensed injectable product made in the Netherlands and imported.2 Clozapine is sometimes administered together with a long-acting antipsychotic in Canadian and U.S. clinics but is generally reserved for the most refractory patients and with close monitoring.3

Editor's Note: This letter was sent to the authors of “Schizophrenia,” who declined to reply.

Email letter submissions to Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors. Letters submitted for publication in AFP must not be submitted to any other publication. Letters may be edited to meet style and space requirements.

This series is coordinated by Kenny Lin, MD, MPH, deputy editor.

Continue Reading

More in AFP

More in Pubmed

Copyright © 2023 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.